3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Psoriasis
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
641
Bevacizumab
552
Paclitaxel
534
Carboplatin
533
Cisplatin
480
pembrolizumab
456
Gemcitabine
422
Docetaxel
415
Rituximab
386
Radiotherapy
373
Dexamethasone
351
Doxorubicin
330
Nivolumab
308
Fluorouracil
286
Capecitabine
260
Etoposide
245
Prednisone
244
Oxaliplatin
242
Erlotinib Hydrochloride
242
Cytarabine
233
Lenalidomide
232
Trastuzumab
226
Pemetrexed
220
Vincristine
212
fludarabine phosphate
208
Leucovorin
208
Cetuximab
208
Filgrastim
204
Bortezomib
193
Methotrexate
183
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Has results
×
Anti-Infective Agents, Local
×
Clear all
NCT01313221
2017-03-15
REFINE
Amgen
Phase 3
Completed
310 enrolled
32 charts